Latest news with #BalaCynwyd
Associated Press
21 hours ago
- Business
- Associated Press
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Carisma Therapeutics Inc. (Nasdaq - CARM), Guaranty Bancshares, Inc. (NYSE - GNTY), MRC Global Inc. (NYSE - MRC), Turnstone Biologics Corp. (Nasdaq - TSBX)
BALA CYNWYD, Pa., June 27, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847. There is no cost or financial obligation to you. Carisma Therapeutics Inc. (Nasdaq - CARM) Under the terms of the Merger Agreement, Carisma will be acquired by OrthoCellix, Inc. (OrthoCellix), a wholly-owned subsidiary of Ocugen, Inc. (Nasdaq - OCGN). Upon the closing of the proposed transactions, existing Carisma stockholders are expected to own approximately 10% of the combined company. The investigation concerns whether the Carisma Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including the dilution to the Company's shareholders in the combined entity. Additional information can be found at Guaranty Bancshares, Inc. (NYSE - GNTY) Under the terms of the agreement, Guaranty will be acquired by Glacier Bancorp, Inc. ('Glacier') (NYSE - GBCI). Guaranty shareholders are to receive 1.0000 share of Glacier stock for each Guaranty share. Based on the closing price of $41.58 for Glacier shares on June 23, 2025, the transaction would result in aggregate consideration of $476.2 million and value of $41.58 per Guaranty share. The investigation concerns whether the Guaranty Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal provides fair value to the Company's shareholders. Additional information can be found at MRC Global Inc. (NYSE - MRC) Under the terms of the Merger Agreement, MRC will be acquired by DNOW Inc. ('DNOW') (NYSE - DNOW). MRC shareholders will receive 0.9489 shares of DNOW common stock for each share of MRC common stock. Upon completion of the transaction, DNOW and MRC shareholders will respectively own approximately 56.5% and approximately 43.5% of the combined company on a fully diluted basis. The investigation concerns whether the MRC Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including the dilution to the Company's shareholders in the combined entity. Additional information can be found at Turnstone Biologics Corp. (Nasdaq - TSBX) Under the terms of the agreement, Turnstone will be acquired by XOMA Royalty Corporation ('XOMA Royalty') (Nasdaq - XOMA) for $0.34 in cash per share of Turnstone common stock plus one non-transferable contingent value right ('CVR'). The investigation concerns whether the Turnstone Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company's shareholders. Additional information can be found at Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.
Yahoo
4 days ago
- Business
- Yahoo
AM Best Comments on Credit Ratings of Philadelphia Insurance Companies' Members; Tokio Marine America Group and First Insurance Company of Hawaii, Ltd.'s Subsidiaries
OLDWICK, N.J., June 24, 2025--(BUSINESS WIRE)--AM Best has commented that the Credit Ratings (ratings) of Philadelphia Indemnity Insurance Company and its affiliate, Tokio Marine Specialty Insurance Company (both headquartered in Bala Cynwyd, PA), which operate under a pooling agreement, collectively referred to as Philadelphia Insurance Companies (Philadelphia); along with Tokio Marine America Group and First Insurance Company of Hawaii, Ltd.'s (FICOH) (Honolulu, HI) subsidiaries remain unchanged following the organization's announcement that it sustained an information security event, which has resulted in a widespread network outage impacting Philadelphia, Tokio Marine America Group and FICOH's systems. On June 9, 2025, the organization received an alert regarding suspicious activity on its IT network. The organization took immediate actions to respond to the situation and disconnected affected systems to contain the threat. AM Best notes that the organization notified law enforcement and is engaged in a comprehensive forensic analysis, which is currently ongoing to determine the full scope, nature and ultimate impact to the organization. Philadelphia, Tokio Marine America Group and FICOH have activated their business continuity plans, including interim solutions that enable employees to carry out essential functions, while system restoration efforts are underway. While the situation continues to evolve, AM Best will continue to monitor the cyber event for any signs that the incident may impair the company's operational capabilities, harm its reputation or market position, or prompt a reassessment of its enterprise risk management capabilities. This press release relates to Credit Ratings that have been published on AM Best's website. For all rating information relating to the release and pertinent disclosures, including details of the office responsible for issuing each of the individual ratings referenced in this release, please see AM Best's Recent Rating Activity web page. For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best's Credit Ratings. For information on the proper use of Best's Credit Ratings, Best's Performance Assessments, Best's Preliminary Credit Assessments and AM Best press releases, please view Guide to Proper Use of Best's Ratings & Assessments. AM Best is a global credit rating agency, news publisher and data analytics provider specializing in the insurance industry. Headquartered in the United States, the company does business in over 100 countries with regional offices in London, Amsterdam, Dubai, Hong Kong, Singapore and Mexico City. For more information, visit Copyright © 2025 by A.M. Best Rating Services, Inc. and/or its affiliates. ALL RIGHTS RESERVED. View source version on Contacts Thomas Keelan Financial Analyst +1 908 882 1925 Edin Imsirovic Director +1 908 882 1903 Charles Chiang Senior Financial Analyst +8 522 827 3427 Christopher Sharkey Associate Director, Public Relations +1 908 882 2310 Al Slavin Senior Public Relations Specialist +1 908 882 2318 Sign in to access your portfolio
Associated Press
19-05-2025
- Business
- Associated Press
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Inozyme Pharma, Inc. (Nasdaq – INZY), TXNM Energy, Inc. (NYSE - TXNM), Servotronics, Inc. (NYSE American - SVT), Protagenic Therapeutics, Inc. (Nasdaq – PTIX)
BALA CYNWYD, Pa., May 19, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847. There is no cost or financial obligation to you. TXNM Energy, Inc. (NYSE - TXNM) Under the terms of the agreement, TXNM Energy will be acquired by Blackstone Infrastructure for $61.25 per share in cash, reflecting a total enterprise value of $11.5 billion. The investigation concerns whether the TXNM Energy Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the consideration provides fair value to the Company's shareholders. Additional information can be found at Inozyme Pharma, Inc. (Nasdaq – INZY) Under the terms of the Merger Agreement, Inozyme Pharma will be acquired by BioMarin Pharmaceutical Inc. ('BioMarin') (Nasdaq – BMRN) for $4.00 per Inozyme Pharma share in an all-cash transaction for a total consideration of approximately $270 million. The investigation concerns whether the Inozyme Pharma Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal provides fair value to the Company's shareholders. Additional information can be found at Servotronics, Inc. (NYSE American - SVT) Under the terms of the agreement, Servotronics will be acquired by TransDigm for $38.50 per share in cash, in a transaction valued at approximately $110 million. The investigation concerns whether the Servotronics Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the consideration provides fair value to the Company's shareholders. Additional information can be found at Protagenic Therapeutics, Inc. (Nasdaq – PTIX) Under the terms of the Merger Agreement, Protagenic Therapeutics will be acquired by Phytanix Bio Inc. ('Phytanix') Ownership of the combined company will be approximately 35% for Protagenic Therapeutics stockholders and approximately 65% for Phytanix stockholders. The investigation concerns whether the Protagenic Therapeutics Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including the dilution to the Company's shareholders in the combined company. Additional information can be found at Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.
Associated Press
19-05-2025
- Business
- Associated Press
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Landsea Homes Corporation (Nasdaq - LSEA), LENSAR, Inc. (Nasdaq - LNSR), AvidXchange Holdings, Inc. (Nasdaq – AVDX), FARO Technologies, Inc. (Nasdaq – FARO)
BALA CYNWYD, Pa., May 19, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847. There is no cost or financial obligation to you. Landsea Homes Corporation (Nasdaq - LSEA) Under the terms of the agreement, Landsea Homes will be acquired by New Home Co. ('New Home') for $11.30 per share in cash. The investigation concerns whether the Landsea Homes Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company's shareholders. For example, the deal consideration is below the 52-week high of $14.04 for the Company's shares. Additional information can be found at LENSAR, Inc. (Nasdaq - LNSR) Under the terms of the Merger Agreement, LENSAR will be acquired by Alcon for $14.00 per share in cash for each LENSAR share, with an additional non-tradeable contingent value right offering up to $2.75 per share in cash, conditioned on achievement of 614,000 cumulative procedures with LENSAR's products between January 1, 2026, and December 31, 2027. The investigation concerns whether the LENSAR Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the Company's shareholders are receiving fair value for their shares. Additional information can be found at AvidXchange Holdings, Inc. (Nasdaq – AVDX) Under the terms of the agreement, AvidXchange Holdings will be acquired by TPG (Nasdaq – TPG) for $10.00 a share in cash in a transaction that values AvidXchange Holdings at $2.2 billion. The investigation concerns whether the AvidXchange Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company's shareholders. Additional information can be found at FARO Technologies, Inc. (Nasdaq – FARO) Under the terms of the Merger Agreement, FARO will be acquired by AMETEK, Inc. (NYSE - AME) for $44 per share in cash. The investigation concerns whether the FARO Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including the dilution of the Company's shareholders in the combined company. Additional information can be found at Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.
CBS News
12-05-2025
- Health
- CBS News
New device helps patients cope with tinnitus, Pennsylvania audiologist says
A growing number of patients are turning to a new treatment for a condition that causes ringing in the ears. The device tricks the brain with a tickle to the tongue. Silence really is golden for Clara Flores. Her days used to be filled with the constant buzzing and ringing that comes with tinnitus, which affects 25 million Americans. "This ringing that you hate and can't stand ... you cannot turn it off," Flores said. "You get depressed, you get angry. Your relationships suffer." But the maddening noise is not a hearing problem, according to Bala Cynwyd audiologist Gail Brenner. "Tinnitus is a sound that we perceive in our ears or head that's internally generated by the brain," Brenner said. And now, for the first time, she says there's finally a treatment that works for most patients Lenire is an FDA-approved device that works with headphones and a tongue stimulator. The electrical pulses from the device "feel like bubbly Champagne," she said. "It's just a tiny little tingle, and that's all we need for the signal to transmit to the brain." Lenire costs $4,000 and isn't covered by insurance. It worked for Flores, who listened to the soothing sounds with the mouthpiece for 12 weeks — twice a day for half an hour. "It did magic to my brain," Flores said. The maker of Lenire says it works by retraining the brain not to hear the sounds from tinnitus that can be caused by loud noise, hearing loss and infections. "We're teaching the brain to not pay attention to the tinnitus," Brenner said. "It has been a game-changer." Flores thinks her tinnitus was caused by an infection, but she doesn't notice the buzzing anymore. "It doesn't bother me. I forget about it," Flores said. Her brain is refocused and noise-free now, giving her a new lease on life. Research on the Lenire device showed that about 80% of the people who tested it had significant improvements.
